Abstract: Novel vitamin D analogues are useful for making pharmaceutical compositions for the prevention or treatment of bone disorders such as osteoporosis.

Abstract: The present invention relates to 7-(2-cyclohexylidene-ethylidene)-spiro[4.5]-decanes, compositions which comprise said 7-(2-cyclohexylidene-ethylidene)-spiro[4.5]-decanes, and methods for treating diseases, illnesses, and the like with said 7-(2-cyclohexylidene-ethylidene)-spiro[4.5]decanes.

Abstract: Novel vitamin D analogues are useful for making pharmaceutical compositions for the prevention or treatment of bone disorders such as osteoporosis

Abstract: Novel vitamin D analogues are useful for making pharmaceutical compositions for the prevention or treatment of bone disorders such as osteoporosis.

Abstract: This invention relates to antagonists of placental growth factor and signalling thereof, pharmaceutical compositions containing such antagonists and the use of such antagonists to prevent bone loss or bone mass and to enhance bone healing including the treatment of conditions which present with low bone mass and/or bone defects in vertebrates, and particularly mammals, including humans.

Abstract: Novel vitamin D analogues are useful for making pharmaceutical compositions for the prevention or treatment of bone disorders such as osteoporosis

Abstract: The present invention relates to analogues of vitamin D namely 14-epi-2-alkyl-19-nor vitamin D derivatives. Also a general method for the synthesis and the biological activities are described. The general formula is: (I) where R (? or ? oriented) represents an alkyl substituent and X part of a typical side chain of vitamin D or of one of its established analogues.

Abstract: The present invention relates to 7-(2-cyclohexylidene-ethylidene)-spiro[4.5]-decanes, compositions which comprise said 7-(2-cyclohexylidene-ethylidene)-spiro[4.5]-decanes, and methods for treating diseases, illnesses, and the like with said 7-(2-cyclohexylidene-ethylidene)-spiro[4.5]decanes.

Abstract: The present invention relates to the vitamin D3 analog (1R,3R)-5-{(E)-(2R, 5R)-2-[2-(4-hydroxy-4-methylpentyl)-spiro[4.5]dec-7-ylidene]-ethylidene}-cyclohexane-1,3-diol which is useful in the treatment of osteoporosis.

Abstract: This invention relates to antagonists of the placental growth factor receptor and signaling thereof, pharmaceutical compositions containing such antagonists and the use of such antagonists to prevent bone loss or bone mass and to enhance bone healing including the treatment of conditions which present with low bone mass and/or bone defects in vertebrates, and particularly mammals, including humans.

Abstract: This invention relates to antagonists of placental growth factor and signalling thereof, pharmaceutical compositions containing such antagonists and the use of such antagonists to prevent bone loss or bone mass and to enhance bone healing including the treatment of conditions which present with low bone mass and/or bone defects in vertebrates, and particularly mammals, including humans.

Abstract: The invention relates to a eukaryotic nuclear protein NuSAP which is highly expressed in proliferation tissues. More specifically, NuSAP is downregulated in developing bone. NuSAP has a discrete localization in the nucleus. The localization and the expression profile indicate its role in important biological processes such as embryologic development, cell, proliferation, DNA replication and recombination. Its function relates to diseases of the immune system and diseases of the reproductive organs in particular and cancer in general.

Abstract: A compound of the formula I: in which P is hydrogen or alkyl; Y and Y′ are each hydrogen or, when taken together, represent a group ═CH2; W and W′ are each hydrogen; X is selected from the group consisting of a hydroxyalkyl, a hydroxyalkoxy, an alkoxy optionally comprising an epoxide function, a hydroxyalkene, a hydroxyalkadiene, a hydroxyalkyne and isomeric forms thereof; and a) either R1 and R3 or R′3 form a saturated 5- or 6-membered carbocyclic ring and R2, R′2, R3 or R′3, R4, R′4, R5 and R′5 are each independently hydrogen or alkyl; or b) R2 or R′2 and R4 or R′4 form a saturated 5- or 6-membered carbocyclic ring, and R1, R2 or R′2, R3, R′3, R4 or R′4, R5 and R′5 are each independently hydrogen or alkyl; or c) R3 or R′3 and R5 or R′5 form a saturated or unsaturated 5- or 6-membered carbocyclic ring, and R1, R2, R′2, R3 or R′3, R4, R′4, and R5 or R′5 are each indep

Abstract: The present invention relates to analogues of vitamin D, which lack the combined presence of the trans-fused six-membered C-ring and of five-membered D-ring, but still possess a central part consisting of a substituted chain of five atoms, atoms which correspond to positions 8, 14, 13, 17 and 20 of vitamin D, and at the ends of which are connected, at position 20 a structural moiety representing part of the side-chain of vitamin D or of an analogue of vitamin D, and at position 8 the .DELTA.(5,7)-diene moiety connected to the A-ring of the active 1-alpha-hydroxy metabolite or of an established vitamin D analogue, to their preparation process, to preparation intermediates, to pharmaceutical preparations comprising these compounds and to their use in medicine.

Abstract: A method for modulating the immune system by administering one or more vitamin D (analogues) to a subject in need of immune therapy, which method may (but need not) include simultaneous treatment with a second immune system modulating active agent. Preferably, the treatment method is used to induce primary or secondary prevention of type I diabetes in a subject susceptible to type I diabetes. Administration of the vitamin D (analogues) is enteral or parenteral.

Abstract: Vitamin D derivatives corresponding to the following formula I ##STR1## in which R.sub.1 denotes a substituted alkyl group having 1 to 15 carbon atoms, in particular the side chains of vitamin D.sub.2 (C.sup.20 to C.sup.28) or D.sub.3 (C.sup.20 to C.sup.

Abstract: Vitamin D derivatives corresponding to the following formula I ##STR1## in which R.sub.1 denotes a substituted alkyl group having 1 to 15 carbon atoms, in particular the side chains of vitamin D.sub.2 (C.sup.20 to C.sup.28) or D.sub.3 (C.sup.20 to C.sup.